Related Experiment Video
Updated: Jun 3, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
FDA-approved preventative therapies for MS: first-line agents
1Virginia Mason Multiple Sclerosis Center, PO Box 900, Seattle, WA 98101, USA. Mariko.Kita@vmmc.org
Abstract:
Relapsing-remitting multiple sclerosis is highly variable in its presentation and disease course. The approach to initiating first-line preventative therapies must focus on individualizing treatment strategies. Careful discussion of available treatment options and appropriate expectations regarding outcomes is important to ensure a successful start. Early treatment is recommended, as is on-going monitoring of patients who may choose to forego therapy.
Related Concept Videos
Alzheimer's Disease: Treatment
Multiple Sclerosis l: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antipsychotic Drugs: Typical and Atypical Agents
Direct-Acting Cholinergic Agonists: Therapeutic Uses
